Pramipexole Accord

Withdrawn

This medicine's authorisation has been withdrawn

pramipexole

Overview

The marketing authorisation for Pramipexole Accord has been withdrawn at the request of the marketing-authorisation holder.

Pramipexole Accord : EPAR - Summary for the public

Reference Number: EMA/684920/2011

Product information

Pramipexole Accord : EPAR - Product Information

Latest procedure affecting product information: IAIN/0017

20/11/2020

This medicine’s product information is available in all official EU languages.
Select 'available languages' to access the language you need.

Product information documents contain:

• summary of product characteristics (annex I);
• manufacturing authorisation holder responsible for batch release (annex IIA);
• conditions of the marketing authorisation (annex IIB);
• labelling (annex IIIA);
• package leaflet (annex IIIB).

Pramipexole Accord : EPAR - All Authorised presentations

Product details

• Name of medicine:
  Pramipexole Accord
• Active substance:
  pramipexole dihydrochloride monohydrate
• International non-proprietary name (INN) or common name:
  pramipexole
• Therapeutic area (MeSH):
  • Parkinson Disease
  • Restless Legs Syndrome
• Anatomical therapeutic chemical (ATC) code:
  N04BC05

Pharmacotherapeutic group

Anti-Parkinson drugs

Therapeutic indication

Pramipexole Accord is indicated in adults for treatment of the signs and symptoms of idiopathic Parkinson's disease, alone (without levodopa) or in combination with levodopa, i.e. over the course of the disease, through to late stages when the effect of levodopa wears off or becomes inconsistent and fluctuations of the therapeutic effect occur (end-of-dose or 'on-off' fluctuations).

Authorisation details

• EMA product number:
  EMEA/H/C/002291
• Generic:

  This is a generic medicine, which is developed to be the same as a medicine that has already been authorised, called the reference medicine. A generic medicine contains the same active substance(s) as the reference medicine, and is used at the same dose(s) to treat the same disease(s). For more information, see Generic and hybrid medicines.

• Marketing authorisation holder:
  Accord Healthcare S.L.U.

  Edificio Este Planta 6a; World Trade Center; Moll De Barcelona S/n; 08039 Barcelona; SPAIN

• Opinion adopted:
  21/07/2011
• Marketing authorisation issued:
  29/09/2011
• Revision:
  10

Assessment history

Changes since initial authorisation of medicine

Pramipexole Accord : EPAR - Procedural steps taken and scientific information after authorisation

Initial marketing authorisation documents

Pramipexole Accord : EPAR - Public assessment report

AdoptedReference Number: EMA/816841/2011

CHMP summary of positive opinion for Pramipexole Accord

AdoptedReference Number: EMA/CHMP/507521/2011